Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.In a phase II study Acadia Pharmaceuticals drug candidate ACP-103 was shown to reduce muscular quivering, a side effect often associated with antipsychotics such as haloperidol.
Subscribe to our email newsletter
Akathisia, or quivering of the muscles, is a debilitating side effect often experienced by patients with schizophrenia who are prescribed such antipsychotics.
This study is one of two phase II clinical trials in Acadia’s program using ACP-103 adjunctively with other antipsychotic drugs to provide an improved therapy for schizophrenia patients.
In addition to this study, Acadia is currently conducting a phase II trial with up to 400 patients, which is designed to evaluate the ability of ACP-103 to improve both the efficacy and safety profile of current antipsychotic drugs.
“We are encouraged by the ability of ACP-103 to treat haloperidol-induced akathisia in patients with schizophrenia,” said Dr Uli Hacksell, Acadia’s CEO. “This study is an important demonstration of our ACP-103 adjunctive therapy approach to improve the quality of care for patients suffering from schizophrenia.”